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Smmary Results from model tumour systems suggest that either increased levels of certain metallo-
proteases (MMPs) or decreased levels of their inhibitors correlate with metastatic potential. In this study,
levels of two MMPs, i.e. MMP-8 and -9, and their inhibitor tissue inhibitor of metalloprotease type I
(TIMP-1) were measured by enzyme-linked immunosorbent assay in human breast tumours. Levels of MMP-8
and -9 correlated significantly with each other, but neither MMP correlated with urokinase plasminogen
activator. Levels of both MMP-8 and -9 were also significantly related to levels of TIMP-1. In contrast.
neither MMP correlated with plasminogen activator inhibitor. No relationship was found between MMP-8,
MMP-9 or TIMP-l and either tumour size or metastasis to axillary nodes. MMP-8 and -9 levels were inversely
related to levels of oestrogen receptors. MMP-8 but not MMP-9 levels were also inversely correlated with
progesterone receptor levels. It is concluded that the assay for MMP-8 and -9 described here will permit the
evaluation of these proteases as prognostic markers in cancer.
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The matrix metalloproteases (MMPs) are a family of zinc
dependent endoproteases which catalyse the degradation of
several different molecules in the extracellular matrix (ECM)
(for reviews, see Woesner, 1991; Aznavooran et al., 1993).
The family can be divided into three main groups: interstitial
collagenases, type IV collagenases or gelatinases and
stromelysins. Interstitial collagenases degrade type I, II and
III collagen. Neutrophil collagenase, which is also known as
MMP-8, appears to have similar substrate speificity to the
interstitial collagenases (Hasty et al., 1990). Type IV col-
lagenases are so named as they cleave the helical portions of
type IV collagen, a form of collagen found at high levels in
basement membranes. In addition, type IV collagenase can
degrade type V, VII, IX and X collagens (Aznavooran et al.,
1993). Two main forms of type IV collagenase have been
described with molecular weights of 72 and 92 kDa. These
two forms are also known as MMP-2 and MMP-9 respec-
tively. The stromelysins have a broad substrate specificity,
degrading molecules such as fibronectin, laminin, proteo-
glycans and the non-helical portions of type IV collagen
(Woessner, 1991; Aznavooran et al., 1993).
Two specific endogenous inhibitors have been described for
the MMP, i.e. TIMP-1 and TIMP-2 (Woessner, 1991;
Aznavooran et al., 1993). TIMP-1 and -2 have molecular
weights of 28 000 and 21 000 respectively and appear to act
by forming 1:1 stoichiometric complexes with the active
MMP. However, TIMP-1 also binds to the precursor form of
MMP-9 (Stetler-Stevenson et al., 1989), while TIMP-2 binds
to the precursor form of MMP-2 (Wilhelm et al., 1989).
Considerable evidence suggests that certain members of the
MMP family play a role in cancer invasion and metastasis, at
least in model systems. Thus, both interstitial and type IV
collagenases correlate with metastatic phenotype in various
cell types (reviewed in Duffy, 1992; Aznavooran et al., 1993).
In addition, inhibitory antibodies against the 72 kDa form of
collagenase IV decrease the penetration of melanoma cells
through reconstituted basement membranes (Hoyhtya et al.,
1990). Similarly, administration of recombinant TIMP-1 to
nude mice has been found to reduce the colonisation of lungs
by metastatic embryo cells (Alvarez et al., 1990), while
TIMP-2 has been shown to block extracellular matrix deg-
radation by cancer cells (DeClerck et al., 1991). Furthermore,
transfection of metastatic rat cells with cDNA for TIMP-2
suppresses the invasive phenotype of these cells (DeClerck et
al., 1992). Finally, down-regulation of the expression of
TIMP-1 by antisense mechanism confers tumorigenic and
metastatic properties on Swiss T3T cells (Khokha et al.,
1989). All these findings suggest that either increased levels of
certain MMPs or decreased levels of their inhibitors could
enhance the metastatic properties of malignant cells.
While MMPs and TIMPs have been extensively inves-
tigated in cell lines, relatively few studies have been carried
out in human tumours, especially using quantitative assays.
The purpose of this investigation was therefore to use an
enzyme-linked immunosorbent assay (ELISA) to measure
two of these MMPs, i.e. MMP-8 and -9, in a series of human
breast tumours and relate these levels to established prognos-
tic markers in breast cancer. We also assayed TIMP-1 by
ELISA in the same series of tumours.
Materils and methods
Breast tumours were homogenised in 50 mM Tris-HCl buffer
pH 7.4 containing 1 mM monothioglycerol. Homogenates
were centrifuged at 2000 g for 10 min. ELISAs for MMP-8,
MMP-9 and TIMP-1 were carried out on the supernatants,
as previously described in detail (Bergmann et al., 1989;
Gunther et al., 1994). The ELISAs for MMP-8 and -9 detect
both precursor and active metalloprotease. Furthermore,
these ELISAs detect MMP-8 and -9 complexes with TIMP-1
but not complexes of these proteases with M2-macroglobulin.
The ELISA for TIMP-1 used polyclonal antibodies and
detects TIMP-1 even in the presence of a 10-fold excess of
either active or latent MMP-8 and -9. Assays for urokinase
plasminogen activator (uPA), tissue-type plasminogen
activator (tPA) and plasminogen activator inhibitor type I
(PAI-1) were also carried out by ELISA using kits supplied
by American Diagnostica (Greenwich, CT, USA). Oestrogen
(ER) and progesterone receptors (PR) were assayed as
previously described by us (Duffy et al., 1986, 1988).
Pathological characteristics and steroid receptor status of the
cancers used are summarised in Table I. Statistical analysis
was carried out using the Spearman coefficient of rank cor-
relation test.
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Table I Histological characteristics and steroid receptor status of
tumours used
n
Tumour size
<2cm 22
>2cm 31
Nodal Status
Negative 23
Positive 19
ER status
Negative 22
Positive 29
PR status
negative 15
positive 16
Please note that not all data were available for all the samples.
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The levels of MMP-8 in the breast tumours varied from 0.36
to 182.5 ngmg-' protein, the median value being 6.47
ngmg-' protein. The corresponding range for MMP-9 was
4-665.3 ngmg-' protein with a median value of 47.6
ngmg-1 protein. Median levels for TIMP-1 were 13.24
ngmg-' protein with a range of 1.7-53.0 ngmg-' protein.
Levels of MMP-8 correlated significantly with levels of
MMP-9 (r=0.66, P<0.001, n=55) (Figure 1). However,
neither metalloprotease correlated significantly with levels of
uPA or tPA. Levels of both MMP-8 and -9 were also
significantly related to concentration ofTIMP-1 (for MMP-8,
r=0.401, P=0.0035, n=54; for MMP-9, r=0.422,
P=0.0021, n=54) (Figure 2). Levels of MMP-8 and -9 were,
however, not related to levels of PAI-1, an inhibitor of the
plasminogen activators.
Levels of MMP-8, MMP-9 and TIMP-1 showed no
significant correlation with either tumour size or axillary
node metastasis. However, both MMP-8 and -9 showed an
inverse relationship with ER levels (for MMP-8, r= -0.369,
P=0.0107, n=49; for MMP-9, r= -0.355, P=0.014, n=49)
(Figure 3). MMP-8 but not MMP-9 also correlated inversely
with PR levels (r=-0.442, P=0.0132, n=32) (Figure 4).
Dbessiom
Previous assays to detect MMPs in human tumour tissue
have used either immunocytochemistry (Monteagudo et al.,
1990), Western blotting (Stearns et al., 1993) or zymography
(Brown et al., 1993; Davies et al., 1993) at the level of
protein and either in situ hybridisation (Poulsom et al., 1992;
Urbanski et al., 1992) or Northern blotting analysis at the
level of mRNA (Urbanski et al., 1992). In addition, TIMP-1
has also been detected by Northern blotting (Urbanski et al.,
1992). Unlike the ELISAs described in this investigation,
these techniques are difficult to quantitate.
MMP-9 has however, been assayed by ELISA in plasma
from patients with breast and other malignancies (Zucker et
al., 1993). In this study, higher plasma levels of MMP-9 were
found in patients with both breast and colorectal cancers
when compared with levels in healthy subjects. In contrast,
MMP-9 levels in plasma from patients with cancers of the
lung, genitourinary tract and lymphomas-leukaemias did not
differ significntly from those in healthy controls.
Using ELISA, we show here that levels of MMP-8 and -9
correlate significantly with one another. Since MMP-8 has
only been found in leucocytes, this finding suggests that both
proteases in breast tumours may be derived, at least in part,
from these host cells. In squamous cell carcinomas, mRNA
for MMP-9 was recently found only in eosinophils (Stahle-
Backdall et al., 1993). However, MMP-9 protein was
detected in neutrophils as well as in eosinophils (Stahle-
Backdall et al., 1993). In another study using squamous cell
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carcinomas, mRNA for MMP-9 was found to be expressed
by both malignant cells and macrophages (Pyke et al., 1992).
In this investigation we show that levels of MMP-8 and -9
are significantly related to levels of TIMP-1. Previous studies
using cell ines (Khokha et al., 1989; DeClerck et al., 1991;
Duffy, 1992; Aznavooran et al., 1993) have suggested that
metastatic potential is related to either increased levels of
MMPs or decreased levels of TIMPs. Our data using human
breast tumours would not appear to support these findings
from cell lines. Previously, we have shown that levels of uPA
and its inhibitor PAI-i are also significantly correlated in
human breast cancers (Reilly et al., 1992), while others have
shown that high levels of PAI-I are significantly related to
poor outcome in this disease (Janicke et al., 1993). These
findings with PAM-I and TIMP-1 in human breast cancers are
difficult to reconcile with the data from cell lines suggesting
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that certain protease inhibitors are suppressors of metastasis.
Moreover, the data from human tumours would appear to
suggest that some protease inhibitors (e.g. PAI-1) may be
involved in or potentiate the metastatic process.
In this study, neither MMP-8, MMP-9 nor TIMP-1
showed any significant relationship with pathological charac-
teristics of the tumour, such as size or metastasis to lymph
nodes. Similarly, Brown et al. (1993), using zymography and
a smaller number of breast tumours, found no relationship
between both MMP-9 and 72 kDA gelatinase and these
histological parameters. Other proteases implicated in experi-
mental metastasis such as uPA and cathepsin D (CD) also
show no or only weak relationship with these traditional
markers of breast cancer prognosis (Duffy et al., 1988, 1991;
Janicke et al., 1993; Pujol et al., 1993). Despite these findings,
in most reports both uPA and CD have been shown to
correlate significantly with poor outcome in breast cancer
(for review see Rochefort, 1992; Duffy, 1993). Indeed, in
some studies both these proteases have been shown to be
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prognostic markers in axillary node-negative breast cancer
patients (Rochefort, 1992; Duffy, 1993), the group ofpatients
in whom new indicators of outcome are most urgently
needed.
In contrast to the lack ofcorrelation between both MMP-8
and -9 and histological features of the tumours, both pro-
teases showed an inverse relationship with ER. Previous
reports using both CD and uPA found no significant rela-
tionship between either of these proteases and ER (Dufly et
al., 1991; Janicke et al., 1993). Since the presence of ER is
generally associated with good prognosis in breast cancer, the
inverse relationship between both MMP-8 and -9 and ER
could suggest that high levels of these metalloproteases will
be related to poor patient outcome.
So far, relatively few studies have been carried out to
evaluate MMPs as prognostic markers in cancer. In one
report using node-negative breast cancer patients however,
MMP-2 levels were reported to correlate with local recur-
rences but not with distant metastases (Daidone et al., 1991).
The ELISAs described here for MMP-8 and -9 should permit
an investigation on the possible prognostic value of these
proteases in breast cancer. In a number of model systems,
both uPA and a metalloprotease was required for metastasis
(Ossowski, 1992; Montgomery et al., 1993). If the same
situation applies for human breast cancer, the combined
measurement of a MMP and uPA may provide more prog-
nostic information than uPA alone.
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